Press release
Nosocomial Pneumonia Pipeline Analysis 2024: EMA, PDMA, FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight
Nosocomial Pneumonia Pipeline
Key Takeaways from the Nosocomial Pneumonia Pipeline Report
• DelveInsight's Nosocomial Pneumonia pipeline report depicts a robust space with 13+ active players working to develop 13+ pipeline therapies for Nosocomial Pneumonia treatment.
• The leading companies working in the Nosocomial Pneumonia Market include Aridis Pharmaceuticals, AstraZeneca, BioVersys, Clarametyx Biosciences, Johnsons & Johnsons Pharmaceutical LLC, PriCara Inc., Merck Sharp & Dohme LLC, Pfizer, Bayer, Nektar Therapeutics, Orlando Health Inc., Medline Industries, Cubist Pharmaceuticals LLC, Peninsula Pharmaceuticals Inc., and others.
• Promising Nosocomial Pneumonia Pipeline Therapies in the various stages of development include Ceftolozane/Tazobactam, meropenem (active comparator), Amikacin inhalation solution (BAY41-6551), and others.
• October 2023: Merck Sharp & Dohme LLC announced a study of Phase 1 clinical trials for Ceftolozane/Tazobactam. This is a phase 1, open-label, non-comparative, multicenter clinical study to evaluate the safety, tolerability, and pharmacokinetics of ceftolozane/tazobactam (MK-7625A) in pediatric participants with nosocomial pneumonia (NP). A Phase 1, Open-label, Non-comparative, Multicenter Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Ceftolozane/Tazobactam (MK-7625A) in Pediatric Participants With Nosocomial Pneumonia.
• August 2023: Pfizer announced a study of Phase 4 clinical trials for Zavicefta, Ceftazidime-Avibactam. This is a prospective, single arm, open-label, multi-center clinical study evaluating the effectiveness and safety of CAZ-AVI in participants with HAP (including VAP), who have initiated treatment with CAZ-AVI in an inpatient hospital setting. The duration of antibiotic treatment with the CAZ-AVI is 7-14 days. Participants must receive intravenously (IV) CAZ-AVI in the hospital for at least 7 full days. There are no formal hypothesis tests planned for this study. The number and percent of participants having clinical cure, failure, and indeterminate at TOC visit in the cMITT analysis population will be summarized.
• May 2023: Basilea Pharmaceutical announced a study of Phase 3 clinical trials for Ceftobiprole medocaril. This was a study of the safety and efficacy of ceftobiprole medocaril compared with intravenous (IV) standard-of-care cephalosporin treatment with or without vancomycin in pediatric patients with either hospital-acquired bacterial pneumonia (HAP) or community-acquired bacterial pneumonia (CAP) requiring hospitalization, and requiring intravenous (IV) antibiotic therapy. A Multicentre, Randomized, Investigator-blind, Active-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of Ceftobiprole Versus Intravenous Standard-of-care Cephalosporin Treatment With or Without Vancomycin in Pediatric Patients Aged From 3 Months to Less Than 18 Years With Hospital-acquired Pneumonia or Community-acquired Pneumonia Requiring Hospitalisation.
Request a sample and discover the recent advances in Nosocomial Pneumonia Treatment Drugs @ Nosocomial Pneumonia Pipeline Report- https://www.delveinsight.com/report-store/nosocomial-pneumonia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
In the Nosocomial Pneumonia pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Nosocomial pneumonia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Nosocomial Pneumonia Overview
Nosocomial pneumonia, also known as hospital-acquired pneumonia (HAP), is a type of lung infection that occurs 48 hours or more after a patient is admitted to the hospital and was not incubating at the time of admission. It is a significant cause of morbidity and mortality in hospitalized patients. The most common pathogens involved include Staphylococcus aureus, including methicillin-resistant Staphylococcus aureus (MRSA), Pseudomonas aeruginosa, and other Gram-negative bacilli.
Risk factors for nosocomial pneumonia include mechanical ventilation, prolonged hospital stays, underlying chronic illnesses, immune suppression, and invasive procedures. Symptoms of HAP can include cough, fever, chills, shortness of breath, chest pain, and increased production of purulent sputum.
Diagnosis is based on clinical presentation, chest imaging (such as X-ray or CT scan), and microbiological analysis of respiratory secretions. Blood tests and cultures may also be used to identify the causative organism.
Treatment involves prompt initiation of broad-spectrum antibiotics, which are later tailored based on specific pathogen identification and antibiotic susceptibility results. Preventative measures include hand hygiene, infection control protocols, proper sterilization of medical equipment, and measures to prevent ventilator-associated pneumonia, such as elevating the head of the bed and ensuring adequate oral care.
Effective management of nosocomial pneumonia requires a multidisciplinary approach to minimize the risk of complications and improve patient outcomes.
Find out more about Nosocomial Pneumonia Therapeutics Assessment @ Nosocomial Pneumonia Preclinical and Discovery Stage Products- https://www.delveinsight.com/sample-request/nosocomial-pneumonia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Nosocomial Pneumonia Emerging Drugs Profile
• Tosatoxumab: Aridis Pharmaceuticals
• Suvratoxumab: AstraZeneca
• Rifabutin: BioVersys
• CMTX 101 : Clarametyx Biosciences
Nosocomial Pneumonia Pipeline Therapeutics Assessment
There are approx. 13+ key companies which are developing the Nosocomial Pneumonia therapies. The Nosocomial Pneumonia companies which have their Nosocomial Pneumonia drug candidates in the most advanced stage, i.e. phase III include, Aridis Pharmaceuticals.
DelveInsight's Nosocomial Pneumonia Pipeline Report covers around 13+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
Nosocomial Pneumonia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Intravenous
• Subcutaneous
• Oral
• Intramuscular
Nosocomial Pneumonia Pipeline Products have been categorized under various Molecule types such as
• Monoclonal antibody
• Small molecule
• Peptide
Learn more about the emerging Nosocomial Pneumonia Pipeline Therapies @ Nosocomial Pneumonia Clinical Trials Assessment- https://www.delveinsight.com/sample-request/nosocomial-pneumonia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Scope of the Nosocomial Pneumonia Pipeline Report
• Coverage- Global
• Nosocomial Pneumonia Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Nosocomial Pneumonia Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Nosocomial Pneumonia Companies- Aridis Pharmaceuticals, AstraZeneca, BioVersys, Clarametyx Biosciences, Johnsons & Johnsons Pharmaceutical LLC, PriCara Inc., Merck Sharp & Dohme LLC, Pfizer, Bayer, Nektar Therapeutics, Orlando Health Inc., Medline Industries, Cubist Pharmaceuticals LLC, Peninsula Pharmaceuticals Inc., and others.
• Nosocomial Pneumonia Pipeline Therapies- Ceftolozane/Tazobactam, meropenem (active comparator), Amikacin inhalation solution (BAY41-6551), and others.
Dive deep into rich insights for new drugs for Nosocomial Pneumonia Treatment, Visit @ Nosocomial Pneumonia Market Drivers and Barriers, and Future Perspective- https://www.delveinsight.com/sample-request/nosocomial-pneumonia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Table of Content
1. Introduction
2. Executive Summary
3. Nosocomial Pneumonia: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Nosocomial Pneumonia- DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Tosatoxumab: Aridis Pharmaceuticals
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Suvratoxumab: AstraZeneca
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. Rifabutin : BioVersys
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. CMTX 101 : Clarametyx Biosciences
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Nosocomial Pneumonia Key Companies
21. Nosocomial Pneumonia Key Products
22. Nosocomial Pneumonia- Unmet Needs
23. Nosocomial Pneumonia- Market Drivers and Barriers
24. Nosocomial Pneumonia- Future Perspectives and Conclusion
25. Nosocomial Pneumonia Analyst Views
26. Nosocomial Pneumonia Key Companies
27. Appendix
For further information on the Nosocomial Pneumonia Pipeline therapeutics, reach out to Nosocomial Pneumonia Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/nosocomial-pneumonia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Trending Reports:
• Biochips Market: https://www.delveinsight.com/report-store/biochips-market
• Bone Anchored Hearing Systems Market: https://www.delveinsight.com/report-store/bone-anchored-hearing-systems-market
• Minimal Residual Disease Market: https://www.delveinsight.com/report-store/minimal-residual-disease-market
• Capnography Device Market: https://www.delveinsight.com/report-store/capnography-devices-market
• Pain Management Devices Market: https://www.delveinsight.com/report-store/pain-management-devices-market
• Pressure Ulcers Market Size: https://www.delveinsight.com/report-store/pressure-ulcers-market
• Blood Glucose Monitoring Systems Market: https://www.delveinsight.com/report-store/blood-glucose-monitoring-systems-market
• Dysthymia Market: https://www.delveinsight.com/report-store/major-depressive-disorder-market
• Osteoarthritis Market: https://www.delveinsight.com/report-store/knee-osteoarthritis-market
• Vascular Access Devices Market: https://www.delveinsight.com/report-store/vascular-access-device-market
• Hearing Aid Devices Market: https://www.delveinsight.com/report-store/hearing-aid-devices-market
• Lymphocytopenia Market: https://www.delveinsight.com/report-store/lymphocytopenia-market
• Gaucher Disease Market: https://www.delveinsight.com/report-store/gauchers-disease-market
• Defibrillators Market: https://www.delveinsight.com/report-store/defibrillator-market
• Human Papilomavirus Market: https://www.delveinsight.com/report-store/human-papillomavirus-hpv-market
• Bradycardia Treatment Devices Market: https://www.delveinsight.com/report-store/electrophysiology-devices-market
• Asphyxia Market: https://www.delveinsight.com/report-store/asphyxia-epidemiology-forecast
• Abetalipoproteinemia Market: https://www.delveinsight.com/report-store/abetalipoproteinemia-market
• Acute Agitation And Aggression Market: https://www.delveinsight.com/report-store/acute-agitation-and-aggression-market
• Alpha-mannosidosis Market: https://www.delveinsight.com/report-store/alpha-mannosidosis-market
• Bartonellosis Market: https://www.delveinsight.com/report-store/bartonellosis-market
• Blood Gas And Electrolyte Analyzers Market: https://www.delveinsight.com/report-store/blood-gas-and-electrolyte-analyzers-market
• Cellulitis Market: https://www.delveinsight.com/report-store/cellulitis-market
• Ocular Motility Disturbance Market: https://www.delveinsight.com/report-store/ocular-motility-disturbance-market
• Vitamin A Deficiency Market: https://www.delveinsight.com/report-store/vitamin-a-deficiency-market
Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/asco-conference-coverage
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Nosocomial Pneumonia Pipeline Analysis 2024: EMA, PDMA, FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight here
News-ID: 3507377 • Views: …
More Releases from DelveInsight Business Research
Autistic Disorder Pipeline 2025: In-depth Clinical Trials Analysis and Emerging …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Autistic Disorder pipeline constitutes 25+ key companies continuously working towards developing 25+ Autistic Disorder treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Autistic Disorder Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also…
Hypovolemic Shock Market Growth to Accelerate in Forecast Period (2024-2032), De …
The Hypovolemic Shock market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Hypovolemic Shock pipeline products will significantly revolutionize the Hypovolemic Shock market dynamics.
DelveInsight's "Hypovolemic Shock Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Hypovolemic Shock, historical and forecasted epidemiology as well as the Hypovolemic Shock market trends in the United…
Chronic Insomnia Market to Expand Significantly by 2034, States DelveInsight Rep …
The Chronic Insomnia market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Chronic Insomnia pipeline products will significantly revolutionize the Chronic Insomnia market dynamics.
DelveInsight's "Chronic Insomnia Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Chronic Insomnia, historical and forecasted epidemiology as well as the Chronic Insomnia market trends in the United States,…
Chronic Spontaneous Urticaria Market Growth Projections 2024-2034: DelveInsight …
DelveInsight's "Chronic Spontaneous Urticaria Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Chronic Spontaneous Urticaria, historical and forecasted epidemiology as well as the Chronic Spontaneous Urticaria market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Chronic Spontaneous Urticaria market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Chronic Spontaneous Urticaria…
More Releases for Nosocomial
Nosocomial Pneumonia Pipeline: Key Advances and Emerging Therapies Shaping Treat …
The treatment landscape for Nosocomial Pneumonia continues to advance, driven by the urgent need to combat antibiotic resistance and improve patient outcomes in hospital settings. Despite progress with existing antibiotics, challenges such as multidrug-resistant pathogens and limited effective therapies remain critical concerns. Leading pharmaceutical and biotech companies, including Aridis Pharmaceuticals, AstraZeneca, BioVersys, and Clarametyx Biosciences, are actively developing novel antimicrobials and innovative treatment approaches targeting resistant bacteria and optimizing pneumonia…
Strengthening Patient Safety-Innovations and Growth in the Nosocomial Infection …
In the face of escalating healthcare challenges, the global Nosocomial Infection Treatment Market is poised for transformative growth. Nosocomial infections-also known as hospital-acquired infections (HAIs)-affect an estimated 1 in 10 hospitalized patients worldwide, driving prolonged hospital stays, increased healthcare costs, and elevated morbidity. The nosocomial infection treatment market was valued at approximately USD 33.4 billion in 2023 and is anticipated to reach USD 58.9 billion by 2033, growing at a…
Nosocomial Pneumonia Pipeline, Clinical Trials, FDA Approvals, and Companies 202 …
DelveInsight's, "Nosocomial Pneumonia Pipeline Insight 2024" report provides comprehensive insights about 13+ companies and 13+ pipeline drugs in the Nosocomial Pneumonia pipeline landscape. It covers the Nosocomial Pneumonia pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Nosocomial Pneumonia pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Nosocomial…
Nosocomial Infections Market Size, Industry Analysis 2022
According to Precision Business Insights (PBI) latest report the Global Nosocomial Infections Market is estimated to be valued at USD 4,281.1 million in 2022 and is poised to grow at a significant CAGR of 8.1% over 2022-2028. Global Nosocomial Infections Market by Products (Heat Sterilization Equipment, Low-Temperature Sterilization Equipment, Radiation Sterilization Equipment, Disinfection Equipment), By End Users (Hospitals, Ambulatory Surgical Centre, Medical Institutions, Diagnostic Laboratories, Clinics), and Geography (North America,…
Nosocomial Infection Treatment Market to Witness Robust Expansion by 2024
LP INFORMATION offers a latest published report on Nosocomial Infection Treatment Market Analysis and Forecast 2019-2025 delivering key insights and providing a competitive advantage to clients through a detailed report.
According to this study, over the next five years the Nosocomial Infection Treatment market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2024, from US$ xx million in 2019.…
New Report: Global Nosocomial Infections Market
MarketResearchReports.Biz presents this most up-to-date research on "Nosocomial Infections-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017"
Report, Nosocomial Infections-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016, provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturersacross the globe. A key objective of the Nosocomial Infections Report is to understand the market and pipeline status of the drugs around the Nosocomial…
